메뉴 건너뛰기




Volumn 19, Issue 2, 2008, Pages 75-105

Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): Retroviruses and hepadnaviruses

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 3' FLUOROTHYMIDINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ADEFOVIR; ADEFOVIR DIPIVOXIL; AMDOXOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; APLAVIROC; APRICITABINE; ATAZANAVIR; BCH 10618; BEVIRIMAT; CALANOLIDE A; CAPRAVIRINE; CLEVUDINE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; ELVUCITABINE; EMIVIRINE; GS 393; L 743; PLERIXAFOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; S 353; UNINDEXED DRUG; VIDEC EC;

EID: 50349088218     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020801900205     Document Type: Article
Times cited : (7)

References (163)
  • 1
    • 2342531101 scopus 로고    scopus 로고
    • Antiviral drugs in current clinical use
    • De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30:115-133.
    • (2004) J Clin Virol , vol.30 , pp. 115-133
    • De Clercq, E.1
  • 2
    • 0342297399 scopus 로고
    • 1592U89 succinate - a potent, selective anti-HW carboxylic nucleoside
    • Daluge SM, Good SS, Faletto MB, et al. 1592U89 succinate - a potent, selective anti-HW carboxylic nucleoside. Antiviral Res 1995; 26:A228.
    • (1995) Antiviral Res , vol.26
    • Daluge, S.M.1    Good, S.S.2    Faletto, M.B.3
  • 3
    • 15144339718 scopus 로고    scopus 로고
    • Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy
    • Weverling GJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998; 12:F117-F122.
    • (1998) AIDS , vol.12
    • Weverling, G.J.1    Lange, J.M.2    Jurriaans, S.3
  • 4
    • 0030010446 scopus 로고    scopus 로고
    • Vandevelde M, Witvrouw M, Schmit JC, Sprecher S, De Clercq E, Tassignon JP. ADA, a potential anti-HW drug. AIDS Res Hum Retroviruses 1996; 12:567-568.
    • Vandevelde M, Witvrouw M, Schmit JC, Sprecher S, De Clercq E, Tassignon JP. ADA, a potential anti-HW drug. AIDS Res Hum Retroviruses 1996; 12:567-568.
  • 5
    • 16944362355 scopus 로고    scopus 로고
    • Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein
    • Rice WG, Turpin JA, Huang M, et al. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med 1997; 3:341-345.
    • (1997) Nat Med , vol.3 , pp. 341-345
    • Rice, W.G.1    Turpin, J.A.2    Huang, M.3
  • 6
    • 0035808584 scopus 로고    scopus 로고
    • Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy
    • Goebel FD, Hemmer R, Schmit JC, et al. Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS 2001; 15:33-45.
    • (2001) AIDS , vol.15 , pp. 33-45
    • Goebel, F.D.1    Hemmer, R.2    Schmit, J.C.3
  • 7
    • 0029932336 scopus 로고    scopus 로고
    • Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection - a pilot study
    • Arends S, Vanhalteren E, Kamp W, Schokker J. Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection - a pilot study. Pharm World Sci 1996; 18:30-34.
    • (1996) Pharm World Sci , vol.18 , pp. 30-34
    • Arends, S.1    Vanhalteren, E.2    Kamp, W.3    Schokker, J.4
  • 8
    • 0023741036 scopus 로고
    • Phosphonylmethoxyethyl purine derivatives, a new class of antihuman immunodeficiency virus agents
    • Pauwels R, Balzarini J, Schols D, et al. Phosphonylmethoxyethyl purine derivatives, a new class of antihuman immunodeficiency virus agents. Antimicrob Agents Chemother 1988; 32:1025-1030.
    • (1988) Antimicrob Agents Chemother , vol.32 , pp. 1025-1030
    • Pauwels, R.1    Balzarini, J.2    Schols, D.3
  • 9
    • 0030045493 scopus 로고    scopus 로고
    • Antiretroviral activity and pharmacokinetics in mice of oral bis (pivaloyloxymethyl)-9-(2-phosphonylmethoxethyl) adenine, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl) adenine
    • Naesens L, Balzarini J, Bischofberger N, De Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis (pivaloyloxymethyl)-9-(2-phosphonylmethoxethyl) adenine, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl) adenine. Antimicrob Agents Chemother 1996; 40:22-28.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 22-28
    • Naesens, L.1    Balzarini, J.2    Bischofberger, N.3    De Clercq, E.4
  • 10
    • 0027253824 scopus 로고
    • Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection
    • Heijtink RA, De Wilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993; 21:141-153.
    • (1993) Antiviral Res , vol.21 , pp. 141-153
    • Heijtink, R.A.1    De Wilde, G.A.2    Kruining, J.3
  • 11
    • 0014658604 scopus 로고
    • 3′-Deoxy-3′-fluorothymidine, a new inhibitor of DNA synthesis
    • Langen P, Etzold G, Hintsche R, Kowollik K. 3′-Deoxy-3′-fluorothymidine, a new inhibitor of DNA synthesis. Acta Biol Med Ger 1969; 23:759-766.
    • (1969) Acta Biol Med Ger , vol.23 , pp. 759-766
    • Langen, P.1    Etzold, G.2    Hintsche, R.3    Kowollik, K.4
  • 12
    • 0035794282 scopus 로고    scopus 로고
    • Anti-HIV type 1 activity of 3′ fluoro-3′-deoxythymidine for several different multidrug resitant mutants
    • Kim EY, Vrang L, Öberg B, Merigan TC. Anti-HIV type 1 activity of 3′ fluoro-3′-deoxythymidine for several different multidrug resitant mutants. AIDS Res Hum Retroviruses 2001; 17:401-407.
    • (2001) AIDS Res Hum Retroviruses , vol.17 , pp. 401-407
    • Kim, E.Y.1    Vrang, L.2    Öberg, B.3    Merigan, T.C.4
  • 13
    • 3042693911 scopus 로고    scopus 로고
    • MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: Results from a 4-week phase II study
    • Katlama C, Ghosn J, Tubiana R, et al. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study. AIDS 2004; 18:1299-1304.
    • (2004) AIDS , vol.18 , pp. 1299-1304
    • Katlama, C.1    Ghosn, J.2    Tubiana, R.3
  • 14
    • 0028209166 scopus 로고    scopus 로고
    • De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus type 1 by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38:668-674.
    • De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus type 1 by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38:668-674.
  • 15
    • 0031891516 scopus 로고    scopus 로고
    • AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor
    • Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nat Med 1998; 4:72-77.
    • (1998) Nat Med , vol.4 , pp. 72-77
    • Donzella, G.A.1    Schols, D.2    Lin, S.W.3
  • 16
    • 0038681342 scopus 로고    scopus 로고
    • The bicyclam AMD3100 story
    • De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2:581-587.
    • (2003) Nat Rev Drug Discov , vol.2 , pp. 581-587
    • De Clercq, E.1
  • 17
    • 0028846226 scopus 로고
    • Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally Bioavailable inhibitor of the enzyme
    • Kim EE, Baker CT, Dwyer MD, et al. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally Bioavailable inhibitor of the enzyme. J Am Chem Soc 1995; 117:1181-1182.
    • (1995) J Am Chem Soc , vol.117 , pp. 1181-1182
    • Kim, E.E.1    Baker, C.T.2    Dwyer, M.D.3
  • 18
  • 19
    • 34848826918 scopus 로고    scopus 로고
    • Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz
    • Pham PA, Hendrix CW, Barditch-Crovo P, et al. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antivir Ther 2007; 12:963-969.
    • (2007) Antivir Ther , vol.12 , pp. 963-969
    • Pham, P.A.1    Hendrix, C.W.2    Barditch-Crovo, P.3
  • 20
    • 34250881641 scopus 로고    scopus 로고
    • Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir
    • Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007; 21:1431-1439.
    • (2007) AIDS , vol.21 , pp. 1431-1439
    • Crane, H.M.1    Kestenbaum, B.2    Harrington, R.D.3    Kitahata, M.M.4
  • 21
    • 15744391870 scopus 로고    scopus 로고
    • The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
    • Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005; 67:1268-1282.
    • (2005) Mol Pharmacol , vol.67 , pp. 1268-1282
    • Watson, C.1    Jenkinson, S.2    Kazmierski, W.3    Kenakin, T.4
  • 22
    • 28544434492 scopus 로고    scopus 로고
    • Westby M, van der Ryst. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005; 16:339-354.
    • Westby M, van der Ryst. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005; 16:339-354.
  • 23
    • 33644820755 scopus 로고    scopus 로고
    • Trials of aplaviroc halted in treatment-naïve patients
    • Ryan CT. Trials of aplaviroc halted in treatment-naïve patients. AIDS Clin Care 2005; 17:107-108.
    • (2005) AIDS Clin Care , vol.17 , pp. 107-108
    • Ryan, C.T.1
  • 24
    • 31944441500 scopus 로고    scopus 로고
    • In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection
    • Gu Z, Allard B, de Muys JM, et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:625-631.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 625-631
    • Gu, Z.1    Allard, B.2    de Muys, J.M.3
  • 25
    • 34249290103 scopus 로고    scopus 로고
    • Apricitabine: A novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection
    • Wainberg MA, Cahn P, Bethell R, Sawyer J, Cox S. Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. Antivir Chem Chemother 2007; 18:61-70.
    • (2007) Antivir Chem Chemother , vol.18 , pp. 61-70
    • Wainberg, M.A.1    Cahn, P.2    Bethell, R.3    Sawyer, J.4    Cox, S.5
  • 26
    • 52149107312 scopus 로고    scopus 로고
    • Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1- infected patients failing therapy with M184V and NRTI resistance
    • 22-25 July, Sydney, Australia. Abstract WESS203
    • Cahn P, Altclas J, Martins M, Losso M, Cassetti I, Cooper D. (2007). Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1- infected patients failing therapy with M184V and NRTI resistance. 4th International AIDS Society Conference, 22-25 July 2007, Sydney, Australia. Abstract WESS203
    • (2007) 4th International AIDS Society Conference
    • Cahn, P.1    Altclas, J.2    Martins, M.3    Losso, M.4    Cassetti, I.5    Cooper, D.6
  • 27
  • 28
    • 33748522493 scopus 로고    scopus 로고
    • A guided tour through the antiviral drug field
    • De Clercq E. A guided tour through the antiviral drug field. Future Virology 2006; 1:19-35.
    • (2006) Future Virology , vol.1 , pp. 19-35
    • De Clercq, E.1
  • 29
    • 38749092085 scopus 로고    scopus 로고
    • Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving atazanavir
    • Vergani B, Cicero ML, Vigano O, et al. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving atazanavir. J Clin Virol 2008:154-159.
    • (2008) J Clin Virol , pp. 154-159
    • Vergani, B.1    Cicero, M.L.2    Vigano, O.3
  • 30
    • 0345686713 scopus 로고    scopus 로고
    • PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing
    • Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 2003; 100:13555-13560.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 13555-13560
    • Li, F.1    Goila-Gaur, R.2    Salzwedel, K.3
  • 31
    • 33750695698 scopus 로고    scopus 로고
    • In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)
    • Adamson CS, Ablan SD, Boeras I, et al. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 2006; 80:10957-10971.
    • (2006) J Virol , vol.80 , pp. 10957-10971
    • Adamson, C.S.1    Ablan, S.D.2    Boeras, I.3
  • 32
    • 34347370621 scopus 로고    scopus 로고
    • Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers
    • Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet 2007; 46:589-598.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 589-598
    • Martin, D.E.1    Blum, R.2    Doto, J.3    Galbraith, H.4    Ballow, C.5
  • 33
    • 0141703204 scopus 로고    scopus 로고
    • A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
    • Lin P-F, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A 2003; 100:11013-11018.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 11013-11018
    • Lin, P.-F.1    Blair, W.2    Wang, T.3
  • 34
    • 33645766774 scopus 로고    scopus 로고
    • Envelope conformational changes induced by HIV-1 attachment inhibitors prevent CD4 binding and downstream entry events
    • Ho H-T, Fan L. Nowicka-Sans B, et al. Envelope conformational changes induced by HIV-1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol 2006; 80:4017-4025.
    • (2006) J Virol , vol.80 , pp. 4017-4025
    • Ho, H.-T.1    Fan, L.2    Nowicka-Sans, B.3
  • 35
    • 0030439224 scopus 로고    scopus 로고
    • Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1
    • Currens MJ, Gulakowski RJ, Mariner JM, et al. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 1996; 279:645-651.
    • (1996) J Pharmacol Exp Ther , vol.279 , pp. 645-651
    • Currens, M.J.1    Gulakowski, R.J.2    Mariner, J.M.3
  • 37
    • 50349088545 scopus 로고    scopus 로고
    • De Clercq E. New anti-HIV agents in preclinical or clinical development. Frontiers in Medicinal Chemistry 2004; 1:543-579.
    • De Clercq E. New anti-HIV agents in preclinical or clinical development. Frontiers in Medicinal Chemistry 2004; 1:543-579.
  • 38
    • 0031805095 scopus 로고    scopus 로고
    • S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1
    • Fujiwara T, Sato A, El-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998; 42:1340-1345.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 1340-1345
    • Fujiwara, T.1    Sato, A.2    El-Farrash, M.3
  • 39
    • 0028943355 scopus 로고
    • Use of 2′-Fluoro-5-methyl-beta-L-arabinofurano-syluridine(1-FMAU) as a novel antiviral agent for hepatitis B and Epstein-Barr virus
    • Chu CK, Ma TW, Shanmuganathan K, et al. Use of 2′-Fluoro-5-methyl-beta-L-arabinofurano-syluridine(1-FMAU) as a novel antiviral agent for hepatitis B and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39:979-981.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 979-981
    • Chu, C.K.1    Ma, T.W.2    Shanmuganathan, K.3
  • 40
    • 34248668494 scopus 로고    scopus 로고
    • Twenty-four week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B
    • Yoo BC, Kim JH, Chung YH, et al. Twenty-four week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45:1172-1178.
    • (2007) Hepatology , vol.45 , pp. 1172-1178
    • Yoo, B.C.1    Kim, J.H.2    Chung, Y.H.3
  • 41
    • 3042782464 scopus 로고    scopus 로고
    • A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B
    • Marcellin P, Mommeja-Marin H, Sacks SL, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40:140-148.
    • (2004) Hepatology , vol.40 , pp. 140-148
    • Marcellin, P.1    Mommeja-Marin, H.2    Sacks, S.L.3
  • 42
    • 27144445999 scopus 로고    scopus 로고
    • Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    • Thompson MA, Kessler HA, Eron JJ, et al. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 2005; 19:1607-1615.
    • (2005) AIDS , vol.19 , pp. 1607-1615
    • Thompson, M.A.1    Kessler, H.A.2    Eron, J.J.3
  • 43
    • 34648831495 scopus 로고    scopus 로고
    • The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection
    • Margolis DM, Mukherjee AL, Fletcher CV, et al. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS 2007; 21:2025-2032.
    • (2007) AIDS , vol.21 , pp. 2025-2032
    • Margolis, D.M.1    Mukherjee, A.L.2    Fletcher, C.V.3
  • 44
    • 33747785298 scopus 로고    scopus 로고
    • A5118 Team. Amdoxovir vs placebo with enfuvirtide plus optimized background therapy for HIV-infected subjects failing current therapy
    • Gripshover BM, Ribaudo H, Santana J, et al. A5118 Team. Amdoxovir vs placebo with enfuvirtide plus optimized background therapy for HIV-infected subjects failing current therapy. Antivir Ther 2006; 11:619-623.
    • (2006) Antivir Ther , vol.11 , pp. 619-623
    • Gripshover, B.M.1    Ribaudo, H.2    Santana, J.3
  • 45
    • 19544386471 scopus 로고    scopus 로고
    • TMC114, anovel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
    • De Meyer S, Azijn H, Surleraux D, et al. TMC114, anovel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321.
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 2314-2321
    • De Meyer, S.1    Azijn, H.2    Surleraux, D.3
  • 46
    • 34250854707 scopus 로고    scopus 로고
    • Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance
    • Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007; 21:1449-1455.
    • (2007) AIDS , vol.21 , pp. 1449-1455
    • Boffito, M.1    Winston, A.2    Jackson, A.3
  • 47
    • 33646015668 scopus 로고    scopus 로고
    • The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro
    • Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43:761-770.
    • (2006) Hepatology , vol.43 , pp. 761-770
    • Paeshuyse, J.1    Kaul, A.2    De Clercq, E.3
  • 48
    • 33746215086 scopus 로고    scopus 로고
    • Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells
    • Noser JA, Towers GJ, Sakuma R, Dumont JM, Collins MK, Ikeda Y. Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol 2006; 80:7769-7774.
    • (2006) J Virol , vol.80 , pp. 7769-7774
    • Noser, J.A.1    Towers, G.J.2    Sakuma, R.3    Dumont, J.M.4    Collins, M.K.5    Ikeda, Y.6
  • 50
    • 0027178052 scopus 로고
    • U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication
    • Dueweke TJ, Poppe SM, Romero DL, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993; 37:1127-1131.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 1127-1131
    • Dueweke, T.J.1    Poppe, S.M.2    Romero, D.L.3
  • 51
    • 0032581593 scopus 로고    scopus 로고
    • Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed
    • Bellman PC. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 1998; 12:1333-1340.
    • (1998) AIDS , vol.12 , pp. 1333-1340
    • Bellman, P.C.1
  • 52
    • 12444325183 scopus 로고    scopus 로고
    • HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′- dideoxy-2′,3′- didehydro-5-fluorocytidine (Reverset™)
    • Geleziunas R, Gallagher K, Zhang H, et al. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′- dideoxy-2′,3′- didehydro-5-fluorocytidine (Reverset™). Antivir Chem Chemother 2003; 14:49-59.
    • (2003) Antivir Chem Chemother , vol.14 , pp. 49-59
    • Geleziunas, R.1    Gallagher, K.2    Zhang, H.3
  • 54
    • 4344566602 scopus 로고    scopus 로고
    • Potent antiviral effect of Reverset in HIV-1 infected adults following a single oral dose
    • Stuyver LJ, Schürmann D, Kravec I, et al. Potent antiviral effect of Reverset in HIV-1 infected adults following a single oral dose. Antivir Ther 2004; 9:529-536.
    • (2004) Antivir Ther , vol.9 , pp. 529-536
    • Stuyver, L.J.1    Schürmann, D.2    Kravec, I.3
  • 55
    • 0035114188 scopus 로고    scopus 로고
    • The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication competence and drug resistance
    • Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication competence and drug resistance. J Clin Invest 2001; 107:449-455.
    • (2001) J Clin Invest , vol.107 , pp. 449-455
    • Ono, S.K.1    Kato, N.2    Shiratori, Y.3
  • 56
    • 0001587762 scopus 로고
    • Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides
    • Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci U S A 1986; 83:1911-1915.
    • (1986) Proc Natl Acad Sci U S A , vol.83 , pp. 1911-1915
    • Mitsuya, H.1    Broder, S.2
  • 57
    • 0030870505 scopus 로고    scopus 로고
    • The role of didanosine in the management of HIV-1 infection
    • Gazzard BG, Moyle GJ. The role of didanosine in the management of HIV-1 infection. Antivir Ther 1997; 2:135-147.
    • (1997) Antivir Ther , vol.2 , pp. 135-147
    • Gazzard, B.G.1    Moyle, G.J.2
  • 58
    • 0028785708 scopus 로고
    • L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type i reverse transcriptase
    • Young SD, Britcher SF, Tran LO, et al. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type i reverse transcriptase. Antimicrob Agents Chemother 1995; 39:2602-2605.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 2602-2605
    • Young, S.D.1    Britcher, S.F.2    Tran, L.O.3
  • 59
    • 36749037438 scopus 로고    scopus 로고
    • From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™
    • De Clercq E. From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™. Future Virology 2006; 1:709-715.
    • (2006) Future Virology , vol.1 , pp. 709-715
    • De Clercq, E.1
  • 60
    • 33847120190 scopus 로고    scopus 로고
    • Acyclic nucleoside phosphonates: Past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge
    • De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 2007; 73:911-922.
    • (2007) Biochem Pharmacol , vol.73 , pp. 911-922
    • De Clercq, E.1
  • 61
    • 33748113778 scopus 로고    scopus 로고
    • Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
    • DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43:1-5.
    • (2006) J Acquir Immune Defic Syndr , vol.43 , pp. 1-5
    • DeJesus, E.1    Berger, D.2    Markowitz, M.3
  • 62
    • 34347347164 scopus 로고    scopus 로고
    • Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137
    • Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007; 45:274-279.
    • (2007) J Acquir Immune Defic Syndr , vol.45 , pp. 274-279
    • Ramanathan, S.1    Shen, G.2    Cheng, A.3    Kearney, B.P.4
  • 63
    • 0031047323 scopus 로고    scopus 로고
    • Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: Potential approach towards effective chemotherapy against HIV-1
    • Piras G, Nakade K, Yuasa S, Baba M. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. AIDS 1997; 11:469-475.
    • (1997) AIDS , vol.11 , pp. 469-475
    • Piras, G.1    Nakade, K.2    Yuasa, S.3    Baba, M.4
  • 64
    • 0026513552 scopus 로고
    • Highly potent and selective inhibition of HIV-1 replication by 6-phenyluracil derivatives
    • Baba M, Shigeta S, Tanaka H, et al. Highly potent and selective inhibition of HIV-1 replication by 6-phenyluracil derivatives. Antiviral Res 1992; 17:245-264.
    • (1992) Antiviral Res , vol.17 , pp. 245-264
    • Baba, M.1    Shigeta, S.2    Tanaka, H.3
  • 65
    • 0028329454 scopus 로고
    • Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro
    • Baba M, Shigeta S, Yuasa S, et al. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 1994; 38:688-692.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 688-692
    • Baba, M.1    Shigeta, S.2    Yuasa, S.3
  • 66
    • 0029965190 scopus 로고    scopus 로고
    • Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus
    • Bridges EG, Dutschman GE, Gullen EA, Cheng YC. Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem Pharmacol 1996; 51:731-736.
    • (1996) Biochem Pharmacol , vol.51 , pp. 731-736
    • Bridges, E.G.1    Dutschman, G.E.2    Gullen, E.A.3    Cheng, Y.C.4
  • 67
    • 0026469165 scopus 로고
    • The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl)] cytosine
    • Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl)] cytosine. Antimicrob Agents Chemother 1992; 36:2686-2692.
    • (1992) Antimicrob Agents Chemother , vol.36 , pp. 2686-2692
    • Furman, P.A.1    Davis, M.2    Liotta, D.C.3
  • 68
    • 0031729823 scopus 로고    scopus 로고
    • Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
    • Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-1307.
    • (1998) Nat Med , vol.4 , pp. 1302-1307
    • Kilby, J.M.1    Hopkins, S.2    Venetta, T.M.3
  • 69
    • 0009816185 scopus 로고    scopus 로고
    • Pentafuside (T-20), a novel inhibitor of HIV-1 fusion: Pharmacokinetics in rodents, monkeys and man
    • Venetta T, DiMassimo B, Johnson MR, et al. Pentafuside (T-20), a novel inhibitor of HIV-1 fusion: pharmacokinetics in rodents, monkeys and man. Antiviral Res 1997; 34:A36.
    • (1997) Antiviral Res , vol.34
    • Venetta, T.1    DiMassimo, B.2    Johnson, M.R.3
  • 71
    • 33644818518 scopus 로고    scopus 로고
    • A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    • Chang TT, Gish RG, deMan R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
    • (2006) N Engl J Med , vol.354 , pp. 1001-1010
    • Chang, T.T.1    Gish, R.G.2    deMan, R.3
  • 72
    • 33644822860 scopus 로고    scopus 로고
    • Entecavir versus lamivudine for patients with HBeAg-negative chronic Hepatitis B
    • Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic Hepatitis B. N Engl J Med 2006; 354:1011-1020.
    • (2006) N Engl J Med , vol.354 , pp. 1011-1020
    • Lai, C.L.1    Shouval, D.2    Lok, A.S.3
  • 73
    • 0035890097 scopus 로고    scopus 로고
    • Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
    • Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001; 184:1236-1245.
    • (2001) J Infect Dis , vol.184 , pp. 1236-1245
    • Colonno, R.J.1    Genovesi, E.V.2    Medina, I.3
  • 74
    • 9644291579 scopus 로고    scopus 로고
    • TMC125, a novel next-generation nonucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant humanimmunodeficiency virus type 1
    • Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant humanimmunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 4680-4686
    • Andries, K.1    Azijn, H.2    Thielemans, T.3
  • 75
    • 34147134958 scopus 로고    scopus 로고
    • Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-I: Primary 24-week analysis
    • TMC125-C223 Writing Group
    • TMC125-C223 Writing Group, Nadler JP, Berger DS, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-I: primary 24-week analysis. AIDS 2007; 21:F1-F10.
    • (2007) AIDS , vol.21
    • Nadler, J.P.1    Berger, D.S.2
  • 76
    • 0024416237 scopus 로고
    • Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]
    • Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989; 33:1765-1773.
    • (1989) Antimicrob Agents Chemother , vol.33 , pp. 1765-1773
    • Vere Hodge, R.A.1    Sutton, D.2    Boyd, M.R.3    Harnden, M.R.4    Jarvest, R.L.5
  • 77
    • 0029161145 scopus 로고
    • Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections
    • Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50:396-415.
    • (1995) Drugs , vol.50 , pp. 396-415
    • Perry, C.M.1    Wagstaff, A.J.2
  • 78
    • 33745098314 scopus 로고    scopus 로고
    • Single-dose, patient-initiated famciclovir: A randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis
    • Spruance SL, Bodsworth N, Resnick H, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006; 55:47-53.
    • (2006) J Am Acad Dermatol , vol.55 , pp. 47-53
    • Spruance, S.L.1    Bodsworth, N.2    Resnick, H.3
  • 79
    • 50349097983 scopus 로고    scopus 로고
    • Fried MW, Di Bisceglie AM, Straus SE, Savarese B, Beames MP, Hoofnagle JH. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Hepatology 1992; 16:127a.
    • Fried MW, Di Bisceglie AM, Straus SE, Savarese B, Beames MP, Hoofnagle JH. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Hepatology 1992; 16:127a.
  • 80
    • 0028817865 scopus 로고
    • Hepatic failure and lactic acidosis due to fialuridine (FIAU), and investigational nucleosed analgue for chronic hepatitis B
    • McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), and investigational nucleosed analgue for chronic hepatitis B. N Engl J Med 1995; 333:1099-1105.
    • (1995) N Engl J Med , vol.333 , pp. 1099-1105
    • McKenzie, R.1    Fried, M.W.2    Sallie, R.3
  • 82
    • 0003281557 scopus 로고    scopus 로고
    • Preclinical development of GW433908/VX-175, the water-soluble phosphate prodrug of amprenavir
    • 26-29 September, San Francisco, CA, USA. Abstract 917
    • Furfine ES. Baker C, Boehlert C, et al. Preclinical development of GW433908/VX-175, the water-soluble phosphate prodrug of amprenavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 26-29 September 1999, San Francisco, CA, USA. Abstract 917.
    • (1999) 39th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Furfine, E.S.1    Baker, C.2    Boehlert, C.3
  • 83
    • 0018239438 scopus 로고
    • Trisodium phosphonoformate, a new antiviral compound
    • Helgstrand E, Eriksson B, Johansson NG, et al. Trisodium phosphonoformate, a new antiviral compound. Science 1978; 201:819-821.
    • (1978) Science , vol.201 , pp. 819-821
    • Helgstrand, E.1    Eriksson, B.2    Johansson, N.G.3
  • 84
    • 0028148047 scopus 로고
    • Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections
    • Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48:199-226.
    • (1994) Drugs , vol.48 , pp. 199-226
    • Wagstaff, A.J.1    Bryson, H.M.2
  • 85
    • 31544435514 scopus 로고    scopus 로고
    • Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor
    • Romines KR, Freeman GA, Schaller LT, et al. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 2006; 49:727-739.
    • (2006) J Med Chem , vol.49 , pp. 727-739
    • Romines, K.R.1    Freeman, G.A.2    Schaller, L.T.3
  • 86
    • 0029086733 scopus 로고
    • Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals
    • Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:36-40.
    • (1995) J Acquir Immune Defic Syndr Hum Retrovirol , vol.10 , pp. 36-40
    • Biron, F.1    Lucht, F.2    Peyramond, D.3
  • 87
    • 0032524983 scopus 로고    scopus 로고
    • Selective depletion of DNA precursors: An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus
    • Johns DG, Gao WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 1998; 55:1551-1556.
    • (1998) Biochem Pharmacol , vol.55 , pp. 1551-1556
    • Johns, D.G.1    Gao, W.Y.2
  • 89
    • 0031660989 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 cDNA integration: New aromatic hydroxylated inhibitors and studies of the inhibition mechanism
    • Farnet CM, Wang B, Hansen M, et al. Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother 1998; 42:2245-2253.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 2245-2253
    • Farnet, C.M.1    Wang, B.2    Hansen, M.3
  • 90
    • 0028222149 scopus 로고
    • L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
    • Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A 1994; 91:4096-4100.
    • (1994) Proc Natl Acad Sci U S A , vol.91 , pp. 4096-4100
    • Vacca, J.P.1    Dorsey, B.D.2    Schleif, W.A.3
  • 91
    • 0442268112 scopus 로고    scopus 로고
    • A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
    • Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
    • (1997) N Engl J Med , vol.337 , pp. 725-733
    • Hammer, S.M.1    Squires, K.E.2    Hughes, M.D.3
  • 92
    • 0026058540 scopus 로고
    • Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
    • Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:8495-8499.
    • (1991) Proc Natl Acad Sci U S A , vol.88 , pp. 8495-8499
    • Doong, S.L.1    Tsai, C.H.2    Schinazi, R.F.3    Liotta, D.C.4    Cheng, Y.C.5
  • 93
    • 0030772798 scopus 로고    scopus 로고
    • Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
    • Nevens F, Thomas HC, De Man RA, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113:1258-1263.
    • (1997) Gastroenterology , vol.113 , pp. 1258-1263
    • Nevens, F.1    Thomas, H.C.2    De Man, R.A.3
  • 94
    • 0025218997 scopus 로고
    • Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV
    • Marquez VE, Tseng CK-H, Mitsuya S, et al. Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. J Med Chem 1990; 33:978-985.
    • (1990) J Med Chem , vol.33 , pp. 978-985
    • Marquez, V.E.1    Tseng, C.K.-H.2    Mitsuya, S.3
  • 95
    • 0029038540 scopus 로고
    • The human HIV/ peripheral blood lymphocyte (PBL)-SCID mouse
    • Flanigan ME, Geiger SP, Ford H, Jr., et al. The human HIV/ peripheral blood lymphocyte (PBL)-SCID mouse. J Immunol 1995; 154:6612-6623.
    • (1995) J Immunol , vol.154 , pp. 6612-6623
    • Flanigan, M.E.1    Geiger, S.P.2    Ford Jr., H.3
  • 97
    • 0031849665 scopus 로고    scopus 로고
    • In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
    • Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72:7532-7541,
    • (1998) J Virol , vol.72 , pp. 7532-7541
    • Carrillo, A.1    Stewart, K.D.2    Sham, H.L.3
  • 98
    • 14444268964 scopus 로고    scopus 로고
    • Design, synthesis and biological properties of ABT-378, a highly potent HIV protease inhibitor
    • 22-26 January, Washington D.C, USA. Abstract 14
    • Sham H, Kempf D, Molla A, et al. Design, synthesis and biological properties of ABT-378, a highly potent HIV protease inhibitor. Fourth Conference on Retroviruses and Opportunistic Infections 22-26 January 1997, Washington D.C., USA. Abstract 14.
    • (1997) Fourth Conference on Retroviruses and Opportunistic Infections
    • Sham, H.1    Kempf, D.2    Molla, A.3
  • 99
    • 0030997937 scopus 로고    scopus 로고
    • Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
    • The CAESAR Coordinating Committee
    • The CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-1421.
    • (1997) Lancet , vol.349 , pp. 1413-1421
  • 100
    • 0027407551 scopus 로고
    • Potent and selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase
    • Pauwels R, Andries K, Debyser Z, et al. Potent and selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:1711-1715.
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 1711-1715
    • Pauwels, R.1    Andries, K.2    Debyser, Z.3
  • 101
    • 33646443202 scopus 로고    scopus 로고
    • Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
    • Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-4920.
    • (2006) J Virol , vol.80 , pp. 4909-4920
    • Westby, M.1    Lewis, M.2    Whitcomb, J.3
  • 102
    • 33847237614 scopus 로고    scopus 로고
    • Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
    • Westby M, Smith-Burchnell C, Mori J et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371.
    • (2007) J Virol , vol.81 , pp. 2359-2371
    • Westby, M.1    Smith-Burchnell, C.2    Mori, J.3
  • 103
    • 0029986895 scopus 로고    scopus 로고
    • Uptake and metabolism of BuCast: A glycoprotein processing inhibitor and a potential anti-HIV drug
    • Kang MS. Uptake and metabolism of BuCast: a glycoprotein processing inhibitor and a potential anti-HIV drug. Glycobiology 1996; 6:209-216.
    • (1996) Glycobiology , vol.6 , pp. 209-216
    • Kang, M.S.1
  • 104
    • 0026178939 scopus 로고
    • 6-O-Butanoyl castanospermine (MDL 28 574) inhibits glycoprotein processing and the growth of HIV
    • Taylor DL, Sunkara PS, Liu PS, Kang MS, Bowlin TL, Tyms AS. 6-O-Butanoyl castanospermine (MDL 28 574) inhibits glycoprotein processing and the growth of HIV. AIDS 1991; 5:693-698.
    • (1991) AIDS , vol.5 , pp. 693-698
    • Taylor, D.L.1    Sunkara, P.S.2    Liu, P.S.3    Kang, M.S.4    Bowlin, T.L.5    Tyms, A.S.6
  • 105
    • 50349086002 scopus 로고    scopus 로고
    • Lindstroem S, Sahlberg C, Wallberg H, Kalayanov G, Oden L, Naeslund L, Tricycloalkatrienes as non-nucleoside reverse transcriptase inhibitors. WO/2002/070516. 2002 September 12.
    • Lindstroem S, Sahlberg C, Wallberg H, Kalayanov G, Oden L, Naeslund L, Tricycloalkatrienes as non-nucleoside reverse transcriptase inhibitors. WO/2002/070516. 2002 September 12.
  • 106
    • 44449115313 scopus 로고    scopus 로고
    • Sahlberg C, Zhou X-X. Development of non nucleoside reverse transcriptase inhibitors HIV therapy anti-infective Agents. Anti-Infective Agents in Medicinal Chemistry 2008; 7:101-117.
    • Sahlberg C, Zhou X-X. Development of non nucleoside reverse transcriptase inhibitors HIV therapy anti-infective Agents. Anti-Infective Agents in Medicinal Chemistry 2008; 7:101-117.
  • 107
    • 0023914007 scopus 로고
    • Potent and selective activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside, 3′-fluoro-2,6-diaminopurine-2′,3′-dideoxyriboside, and 3′-fluoro-2′,3′-dideoxyguanosine against human immunodeficiency virus
    • Balzarini J, Baba M, Pauwels R, et al. Potent and selective activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside, 3′-fluoro-2,6-diaminopurine-2′,3′-dideoxyriboside, and 3′-fluoro-2′,3′-dideoxyguanosine against human immunodeficiency virus. Mol Pharmacol 1988; 33:243-249.
    • (1988) Mol Pharmacol , vol.33 , pp. 243-249
    • Balzarini, J.1    Baba, M.2    Pauwels, R.3
  • 108
    • 50349099421 scopus 로고    scopus 로고
    • Zhang H, Öberg B, Harmenberg J, et al. Inhibition of multiple-drug resistant (MDR) HIV-1by 3′-fluro-2′,3′-dideoxyguanosine (FLG). Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2002; 42:H-182.
    • Zhang H, Öberg B, Harmenberg J, et al. Inhibition of multiple-drug resistant (MDR) HIV-1by 3′-fluro-2′,3′-dideoxyguanosine (FLG). Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2002; 42:H-182.
  • 109
    • 33644642052 scopus 로고    scopus 로고
    • In vitro characterization of the anti-HBV acitivity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine
    • Jacquard AC, Brunelle MN, Pichoud C, et al. In vitro characterization of the anti-HBV acitivity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine. Antimicrob Agents Chemother 2006; 50:955-961.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 955-961
    • Jacquard, A.C.1    Brunelle, M.N.2    Pichoud, C.3
  • 110
    • 0028921611 scopus 로고
    • Protein structure based design of potent orally available nonpeptide inhibitors of human immunodeficiency virus protease
    • Reich SH, Melnick M, Davies JF, II, et al. Protein structure based design of potent orally available nonpeptide inhibitors of human immunodeficiency virus protease. Proc Natl Acad Sci U S A 1995; 92:3298-3302.
    • (1995) Proc Natl Acad Sci U S A , vol.92 , pp. 3298-3302
    • Reich, S.H.1    Melnick, M.2    Davies II, J.F.3
  • 111
    • 0030032764 scopus 로고    scopus 로고
    • Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease
    • Shetty BV, Kosa MB, Khalil DA, Webber S. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996; 40:110-114.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 110-114
    • Shetty, B.V.1    Kosa, M.B.2    Khalil, D.A.3    Webber, S.4
  • 112
    • 0025679303 scopus 로고
    • Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor
    • Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 1990; 250:1411-1413.
    • (1990) Science , vol.250 , pp. 1411-1413
    • Merluzzi, V.J.1    Hargrave, K.D.2    Labadia, M.3
  • 113
    • 0030317268 scopus 로고    scopus 로고
    • Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - a randomized, double-blind, placebo-controlled trial
    • D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124:1019-1030.
    • (1996) Ann Intern Med , vol.124 , pp. 1019-1030
    • D'Aquila, R.T.1    Hughes, M.D.2    Johnson, V.A.3
  • 114
    • 36048937589 scopus 로고    scopus 로고
    • Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine
    • Lockman S, McIntyre JA. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. Lancet 2007; 370:1668-1670.
    • (2007) Lancet , vol.370 , pp. 1668-1670
    • Lockman, S.1    McIntyre, J.A.2
  • 115
    • 25044464110 scopus 로고    scopus 로고
    • Anti-HIV activity of PETT-4 in vitro
    • Vrang L, Agreu C, Ekelof K, et al. Anti-HIV activity of PETT-4 in vitro. Antiviral Res 1998; 37:A55.
    • (1998) Antiviral Res , vol.37
    • Vrang, L.1    Agreu, C.2    Ekelof, K.3
  • 116
    • 50349090435 scopus 로고    scopus 로고
    • MIV-150 in a vaginal microbicide with superior anti-HIV activities
    • 12-16 July, Bangkok, Thailand. Abstract TuPeB4667
    • Zhang H, Öberg B, Böttiger D, et al. MIV-150 in a vaginal microbicide with superior anti-HIV activities. XV International SIDS conference, 12-16 July 2004, Bangkok, Thailand. Abstract TuPeB4667.
    • (2004) XV International SIDS conference
    • Zhang, H.1    Öberg, B.2    Böttiger, D.3
  • 118
    • 0023633215 scopus 로고
    • Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine (BRL 39123) in cell culture
    • Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987; 31:1238-1242.
    • (1987) Antimicrob Agents Chemother , vol.31 , pp. 1238-1242
    • Boyd, M.R.1    Bacon, T.H.2    Sutton, D.3    Cole, M.4
  • 119
    • 0030898625 scopus 로고    scopus 로고
    • Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group
    • Spruance SL, Boon R, Saltzman R, Tucker R, Thoming C, Rea TL. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 1997; 277:1374-1379.
    • (1997) JAMA , vol.277 , pp. 1374-1379
    • Spruance, S.L.1    Boon, R.2    Saltzman, R.3    Tucker, R.4    Thoming, C.5    Rea, T.L.6
  • 120
    • 0028028038 scopus 로고
    • Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients
    • Degreef H, Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4:241-246.
    • (1994) Int J Antimicrob Agents , vol.4 , pp. 241-246
    • Degreef, H.1
  • 121
    • 34250209137 scopus 로고    scopus 로고
    • Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells
    • Roth S, Monsour M, Dowland A, et al. (2007) Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells. Antimicrob Agents Chemother 2007; 51:1972-1978.
    • (2007) Antimicrob Agents Chemother , vol.2007 , Issue.51 , pp. 1972-1978
    • Roth, S.1    Monsour, M.2    Dowland, A.3
  • 122
    • 13344262687 scopus 로고    scopus 로고
    • Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities
    • Rusconi S, Moonis M, Merrill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996; 40:234-236
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 234-236
    • Rusconi, S.1    Moonis, M.2    Merrill, D.P.3
  • 123
    • 34250188089 scopus 로고    scopus 로고
    • Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides
    • Gantlett KE, Weber JN, Sattentau QJ, Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res 2007; 75:188-197.
    • (2007) Antiviral Res , vol.75 , pp. 188-197
    • Gantlett, K.E.1    Weber, J.N.2    Sattentau, Q.J.3
  • 124
    • 35548934433 scopus 로고    scopus 로고
    • Racivir demonstrates safety and efficacy in patients harboring HIV with the M184V mutation and less than 3 TAMs
    • Los Angeles, CA, USA, 25-28 February, Abstract 488
    • Cahn P, Sosa N, Wiznia A, et al. Racivir demonstrates safety and efficacy in patients harboring HIV with the M184V mutation and less than 3 TAMs. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, 25-28 February 2007. Abstract 488.
    • (2007) 14th Conference on Retroviruses and Opportunistic Infections
    • Cahn, P.1    Sosa, N.2    Wiznia, A.3
  • 125
    • 17344369052 scopus 로고    scopus 로고
    • Sustained anti-HIV-1 effect of Racivir combined with D4T and Sustiva following a 14-day treatment of infected volunteers
    • 10-14 February, Boston, MA, USA. Abstract 552
    • Otto MJ, Arastèh K, Kreckel P, et al. Sustained anti-HIV-1 effect of Racivir combined with D4T and Sustiva following a 14-day treatment of infected volunteers. 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, MA, USA. Abstract 552.
    • (2003) 10th Conference on Retroviruses and Opportunistic Infections
    • Otto, M.J.1    Arastèh, K.2    Kreckel, P.3
  • 126
    • 17344367908 scopus 로고    scopus 로고
    • Single and multiple dose pharmacokinetics and safety of the nucleoside Racivir in male volunteers
    • 15-19 December, Naples, FL, USA. Abstract 044
    • Otto MJ, Arasteh K, Schulbin H, et al. Single and multiple dose pharmacokinetics and safety of the nucleoside Racivir in male volunteers. Frontiers in Drug Development for Antiretroviral Therapies, HIV DART 2002, 15-19 December 2002, Naples, FL, USA. Abstract 044.
    • (2002) Frontiers in Drug Development for Antiretroviral Therapies, HIV DART 2002
    • Otto, M.J.1    Arasteh, K.2    Schulbin, H.3
  • 127
    • 33845366857 scopus 로고    scopus 로고
    • Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
    • Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-515.
    • (2006) J Acquir Immune Defic Syndr , vol.43 , pp. 509-515
    • Markowitz, M.1    Morales-Ramirez, J.O.2    Nguyen, B.Y.3
  • 128
    • 34147136222 scopus 로고    scopus 로고
    • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial
    • Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
    • (2007) Lancet , vol.369 , pp. 1261-1269
    • Grinsztejn, B.1    Nguyen, B.Y.2    Katlama, C.3
  • 129
    • 20144372481 scopus 로고    scopus 로고
    • In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4- 4-4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]- 2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)
    • Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4- 4-4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]- 2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005; 48:1901-1909.
    • (2005) J Med Chem , vol.48 , pp. 1901-1909
    • Janssen, P.A.1    Lewi, P.J.2    Arnold, E.3
  • 130
    • 33748036988 scopus 로고    scopus 로고
    • Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects
    • Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS 2006; 20:1721-1726.
    • (2006) AIDS , vol.20 , pp. 1721-1726
    • Goebel, F.1    Yakovlev, A.2    Pozniak, A.L.3
  • 131
    • 50349090341 scopus 로고    scopus 로고
    • van 't Klooster G, Verloes R, Baert L et al. Long-acting TMC278, a parenteral depot formulation delivering therapeutic NNRTI concentrations in preclinical and clinical settings. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008 Boston, MA, USA. Oral abstract 134.
    • van 't Klooster G, Verloes R, Baert L et al. Long-acting TMC278, a parenteral depot formulation delivering therapeutic NNRTI concentrations in preclinical and clinical settings. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008 Boston, MA, USA. Oral abstract 134.
  • 132
    • 0028854676 scopus 로고
    • Selection and analysis of human immunodeficiency virus type 1 variant with increased resistance to ABT-538, a novel protease inhibitor
    • Markowitz M, Hongnei MO, Kemp D, et al. Selection and analysis of human immunodeficiency virus type 1 variant with increased resistance to ABT-538, a novel protease inhibitor. J Virol1995; 69:701-706,
    • (1995) J Virol , vol.69 , pp. 701-706
    • Markowitz, M.1    Hongnei, M.O.2    Kemp, D.3
  • 133
    • 0032552144 scopus 로고    scopus 로고
    • A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group
    • Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS 1998; 12:1495-1502.
    • (1998) AIDS , vol.12 , pp. 1495-1502
    • Cohen, C.1    Revicki, D.A.2    Nabulsi, A.3    Sarocco, P.W.4    Jiang, P.5
  • 134
    • 0025268321 scopus 로고
    • Rational design of peptide-based HIV proteinase inhibition
    • Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibition. Science 1990; 248:358-361.
    • (1990) Science , vol.248 , pp. 358-361
    • Roberts, N.A.1    Martin, J.A.2    Kinchington, D.3
  • 135
    • 0031914446 scopus 로고    scopus 로고
    • Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection
    • Perry CM, Noble S. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 1998; 55:461-486.
    • (1998) Drugs , vol.55 , pp. 461-486
    • Perry, C.M.1    Noble, S.2
  • 136
    • 0023124801 scopus 로고
    • Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro
    • Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, Vandeputte M. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 1987; 142:128-134.
    • (1987) Biochem Biophys Res Commun , vol.142 , pp. 128-134
    • Baba, M.1    Pauwels, R.2    Herdewijn, P.3    De Clercq, E.4    Desmyter, J.5    Vandeputte, M.6
  • 137
    • 0023196616 scopus 로고
    • Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene( 3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus
    • Lin TS, Schinazi RF, Prusoff WH. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene( 3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol 1987; 36:2713-2718.
    • (1987) Biochem Pharmacol , vol.36 , pp. 2713-2718
    • Lin, T.S.1    Schinazi, R.F.2    Prusoff, W.H.3
  • 139
    • 0001906815 scopus 로고    scopus 로고
    • HIV-1 isolates from patients treated with T-20 are sensitive to the second generation fusion inhibitor T1249
    • Lambert DM, Zhou J, Medinas R, et al. HIV-1 isolates from patients treated with T-20 are sensitive to the second generation fusion inhibitor T1249. Antivir Ther 1999; 4 Suppl 1:8.
    • (1999) Antivir Ther , vol.4 , Issue.SUPPL. 1 , pp. 8
    • Lambert, D.M.1    Zhou, J.2    Medinas, R.3
  • 140
    • 3042807040 scopus 로고    scopus 로고
    • Telbivudine/torcitabine (Idenix.Novartis)
    • Vere Hodge A. Telbivudine/torcitabine (Idenix.Novartis). Curr Opin Investig Drugs 2003; 5:232-241.
    • (2003) Curr Opin Investig Drugs , vol.5 , pp. 232-241
    • Vere Hodge, A.1
  • 141
    • 0035172399 scopus 로고    scopus 로고
    • Antiviral L-nucleosides specific for hepatitis B virus infection
    • Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45:229-235.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 229-235
    • Bryant, M.L.1    Bridges, E.G.2    Placidi, L.3
  • 142
    • 0027534661 scopus 로고
    • Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine
    • Balzarini J, Holy A, Jindrich J, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993; 37:332-338.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 332-338
    • Balzarini, J.1    Holy, A.2    Jindrich, J.3
  • 143
    • 0028791836 scopus 로고
    • Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine
    • Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270:1197-1199.
    • (1995) Science , vol.270 , pp. 1197-1199
    • Tsai, C.C.1    Follis, K.E.2    Sabo, A.3
  • 144
    • 0031710248 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults
    • Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42:2380-2384.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 2380-2384
    • Deeks, S.G.1    Barditch-Crovo, P.2    Lietman, P.S.3
  • 145
    • 0142126681 scopus 로고    scopus 로고
    • Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections
    • De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569-596.
    • (2003) Clin Microbiol Rev , vol.16 , pp. 569-596
    • De Clercq, E.1
  • 146
    • 0031863214 scopus 로고    scopus 로고
    • Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice
    • Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 1998; 42:1568-1573.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 1568-1573
    • Naesens, L.1    Bischofberger, N.2    Augustijns, P.3
  • 147
    • 12944322516 scopus 로고    scopus 로고
    • Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class
    • Turner SR, Strohbach JW, Tommasi RA, et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41:3467-3476.
    • (1998) J Med Chem , vol.41 , pp. 3467-3476
    • Turner, S.R.1    Strohbach, J.W.2    Tommasi, R.A.3
  • 148
    • 0028028221 scopus 로고
    • Structure based design of HIV protease inhibitors: 4-hydroxy coumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors
    • Thaisrivongs S, Tomich PK, Watenpaugh KD, et al. Structure based design of HIV protease inhibitors: 4-hydroxy coumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem 1994; 37:3200-3204.
    • (1994) J Med Chem , vol.37 , pp. 3200-3204
    • Thaisrivongs, S.1    Tomich, P.K.2    Watenpaugh, K.D.3
  • 149
    • 0028029961 scopus 로고
    • New [4,5,1-JK] [1,4]benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 and are synergistic with 2′,3′-dideoxynucleoside analogues
    • Pauwels R, Andries K, Debyser Z, et al. New [4,5,1-JK] [1,4]benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 and are synergistic with 2′,3′-dideoxynucleoside analogues. Antimicrob Agents Chemother 1994; 38:2863-2870.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 2863-2870
    • Pauwels, R.1    Andries, K.2    Debyser, Z.3
  • 150
    • 0028885715 scopus 로고
    • Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives Trovirdine and MSG-127
    • Zhang H, Vrang L, Backbro K, et al. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives Trovirdine and MSG-127. Antiviral Res 1995; 28:331-342.
    • (1995) Antiviral Res , vol.28 , pp. 331-342
    • Zhang, H.1    Vrang, L.2    Backbro, K.3
  • 151
    • 12144265244 scopus 로고    scopus 로고
    • Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present and future
    • De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future. Chem Biodivers 2004; 1:44-64.
    • (2004) Chem Biodivers , vol.1 , pp. 44-64
    • De Clercq, E.1
  • 152
    • 0028998825 scopus 로고
    • The PETT series, a new class of potent non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase
    • Ahgren C, Backro K, Bell FW, et al. The PETT series, a new class of potent non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39:1329-1335.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 1329-1335
    • Ahgren, C.1    Backro, K.2    Bell, F.W.3
  • 153
    • 0022504259 scopus 로고
    • Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs rwelated to buciclovir
    • Larsson A, Stenberg K, Ericsson A-C, et al. Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs rwelated to buciclovir. Antimicrob Agents Chemother 1986; 30:598-605.
    • (1986) Antimicrob Agents Chemother , vol.30 , pp. 598-605
    • Larsson, A.1    Stenberg, K.2    Ericsson, A.-C.3
  • 154
    • 0027245440 scopus 로고
    • Efficacy of (-)-9[4-Hydroxy-2-(Hydroxymethyl)Butyl] Guanine in African green monkeys infected with simian varicella virus
    • Soike KF, Bohm R, Huang J-L, Öberg B. Efficacy of (-)-9[4-Hydroxy-2-(Hydroxymethyl)Butyl] Guanine in African green monkeys infected with simian varicella virus. Antimicrob Agents Chemother 1993; 37:1370-1372.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 1370-1372
    • Soike, K.F.1    Bohm, R.2    Huang, J.-L.3    Öberg, B.4
  • 155
    • 30344486584 scopus 로고    scopus 로고
    • Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy
    • De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006; 147:1-11.
    • (2006) Br J Pharmacol , vol.147 , pp. 1-11
    • De Clercq, E.1    Field, H.J.2
  • 156
    • 23244453590 scopus 로고    scopus 로고
    • A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B
    • Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536.
    • (2005) Gastroenterology , vol.129 , pp. 528-536
    • Lai, C.L.1    Leung, N.2    Teo, E.K.3
  • 157
    • 28944454412 scopus 로고    scopus 로고
    • Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
    • Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49:4911-4919.
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 4911-4919
    • Strizki, J.M.1    Tremblay, C.2    Xu, S.3
  • 158
    • 34250006524 scopus 로고    scopus 로고
    • Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults
    • Schürmann D, Fätkenheuer G. Revnes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-1299.
    • (2007) AIDS , vol.21 , pp. 1293-1299
    • Schürmann, D.1    Fätkenheuer, G.2    Revnes, J.3
  • 159
    • 34347379935 scopus 로고    scopus 로고
    • Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211
    • Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-312.
    • (2007) J Infect Dis , vol.196 , pp. 304-312
    • Gulick, R.M.1    Su, Z.2    Flexner, C.3
  • 160
    • 0001587762 scopus 로고
    • Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides
    • Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci U S A 1986; 83:1191-1915.
    • (1986) Proc Natl Acad Sci U S A , vol.83 , pp. 1191-1915
    • Mitsuya, H.1    Broder, S.2
  • 161
    • 0031740357 scopus 로고    scopus 로고
    • Finding a role for zalcitabine in the HAART era
    • Moyle GJ, Gazzard BG. Finding a role for zalcitabine in the HAART era. Antivir Ther 1998; 3:125-137.
    • (1998) Antivir Ther , vol.3 , pp. 125-137
    • Moyle, G.J.1    Gazzard, B.G.2
  • 162
    • 0001707601 scopus 로고
    • 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
    • Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985; 82:7096-7100.
    • (1985) Proc Natl Acad Sci U S A , vol.82 , pp. 7096-7100
    • Mitsuya, H.1    Weinhold, K.J.2    Furman, P.A.3
  • 163
    • 0029057799 scopus 로고
    • Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness - a meta analysis
    • Ioannidis JPA, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness - a meta analysis. Ann Intern Med 1995; 122:856-866.
    • (1995) Ann Intern Med , vol.122 , pp. 856-866
    • Ioannidis, J.P.A.1    Cappelleri, J.C.2    Lau, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.